233 related articles for article (PubMed ID: 19826134)
1. Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
Oberlin O; Fawaz O; Rey A; Niaudet P; Ridola V; Orbach D; Bergeron C; Defachelles AS; Gentet JC; Schmitt C; Rubie H; Munzer M; Plantaz D; Deville A; Minard V; Corradini N; Leverger G; de Vathaire F
J Clin Oncol; 2009 Nov; 27(32):5350-5. PubMed ID: 19826134
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
Stöhr W; Paulides M; Bielack S; Jürgens H; Treuner J; Rossi R; Langer T; Beck JD
Pediatr Blood Cancer; 2007 Apr; 48(4):447-52. PubMed ID: 16628552
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
Loebstein R; Atanackovic G; Bishai R; Wolpin J; Khattak S; Hashemi G; Gobrial M; Baruchel S; Ito S; Koren G
J Clin Pharmacol; 1999 May; 39(5):454-61. PubMed ID: 10234592
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
Skinner R; Cotterill SJ; Stevens MC
Br J Cancer; 2000 May; 82(10):1636-45. PubMed ID: 10817497
[TBL] [Abstract][Full Text] [Related]
5. Renal dysfunctions secondary to ifosfamide treatment in children.
Tokuc G; Yalçiner A; Kebudi R; Dogan S; Görgün O; Ayan I
J Exp Clin Cancer Res; 1997 Jun; 16(2):227-30. PubMed ID: 9261752
[TBL] [Abstract][Full Text] [Related]
6. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Pediatr Blood Cancer; 2010 Jul; 54(7):983-9. PubMed ID: 20405516
[TBL] [Abstract][Full Text] [Related]
7. Growth impairment after ifosfamide-induced nephrotoxicity in children.
Stöhr W; Patzer L; Paulides M; Kremers A; Beck JD; Langer T; Rossi R
Pediatr Blood Cancer; 2007 May; 48(5):571-6. PubMed ID: 16755549
[TBL] [Abstract][Full Text] [Related]
8. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
Raney B; Ensign LG; Foreman J; Khan F; Newton W; Ortega J; Ragab A; Wharam M; Wiener E; Maurer H
Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):286-95. PubMed ID: 7978043
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide nephropathy in patients with sarcoma.
Mashhadi MA; Sanadgol H; Keikhaei M
Iran J Kidney Dis; 2011 Jul; 5(4):238-41. PubMed ID: 21725180
[TBL] [Abstract][Full Text] [Related]
10. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
Antman K; Crowley J; Balcerzak SP; Kempf RA; Weiss RB; Clamon GH; Baker LH
Cancer; 1998 Apr; 82(7):1288-95. PubMed ID: 9529020
[TBL] [Abstract][Full Text] [Related]
11. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system.
Stöhr W; Paulides M; Bielack S; Jürgens H; Koscielniak E; Rossi R; Langer T; Beck JD
Pediatr Blood Cancer; 2007 Feb; 48(2):140-7. PubMed ID: 16724313
[TBL] [Abstract][Full Text] [Related]
12. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
[TBL] [Abstract][Full Text] [Related]
13. [A prospective study on nephrotoxicity induced by continuous infusion of high-dose ifosfamide (15/m2)].
Ferrari S; Zolezzi C; Bacci G; Pieretti F; Iantorno D; Figus E; Pizzoferrato A
Minerva Pediatr; 1997; 49(1-2):29-37. PubMed ID: 9132558
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide in the treatment of pediatric malignancies.
Voûte PA; van den Berg H; Behrendt H; Michiels E; de Kraker J
Semin Oncol; 1996 Jun; 23(3 Suppl 7):8-11. PubMed ID: 8711502
[TBL] [Abstract][Full Text] [Related]
15. [Ifosfamide in pediatric malignancy--experiences in the Northern Israel Oncology Center].
Roguin A; Ben Arush MW; Higasi A; Kuten A
Harefuah; 1996 Apr; 130(8):511-4, 584. PubMed ID: 8765870
[TBL] [Abstract][Full Text] [Related]
16. Chronic ifosfamide nephrotoxicity in children.
Skinner R
Med Pediatr Oncol; 2003 Sep; 41(3):190-7. PubMed ID: 12868118
[TBL] [Abstract][Full Text] [Related]
17. Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens.
Ridola V; Fawaz O; Aubier F; Bergeron C; de Vathaire F; Pichon F; Orbach D; Gentet JC; Schmitt C; Dufour C; Oberlin O
Eur J Cancer; 2009 Mar; 45(5):814-8. PubMed ID: 19216070
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M
Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807
[TBL] [Abstract][Full Text] [Related]
19. Progressive glomerular toxicity of ifosfamide in children.
Prasad VK; Lewis IJ; Aparicio SR; Heney D; Hale JP; Bailey CC; Kinsey SE
Med Pediatr Oncol; 1996 Sep; 27(3):149-55. PubMed ID: 8699991
[TBL] [Abstract][Full Text] [Related]
20. [Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma].
Chen LK; Xu GC; Teng XY; Liang Y; Liu JL; Zhou XM
Ai Zheng; 2002 Aug; 21(8):903-6. PubMed ID: 12478904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
